Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma reported mixed results for FY2026. Standalone revenue declined to Rs 4,782 Cr from Rs 5,286 Cr in the prior year, while standalone PAT grew marginally to Rs 700 Cr from Rs 691 Cr. However, consolidated results showed a net loss of Rs 326 Cr versus a profit of Rs 91 Cr in FY2025, as consolidated revenue fell to Rs 8,869 Cr from Rs 9,151 Cr. Exceptional items of Rs 196 Cr (consolidated) included impairment of intangible assets and labour code implementation costs. The auditors issued an unmodified opinion. The Board also approved re-appointment of key directors including Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director, both for 3-year terms.
The sharp swing to consolidated net loss despite better standalone performance signals underlying pressure at the subsidiary level. Revenue decline across both standalone and consolidated figures is a concern, though the company maintains positive standalone profitability. Shareholders should monitor the drivers of consolidated losses and exceptional item impact.